Kirby McInerney probes Unicycive after 39% stock drop on FDA letter

The law firm said it is investigating possible federal securities law violations after Unicycive disclosed a second Complete Response Letter tied to the same third-party manufacturing deficiencies cited in June 2025.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.

Kirby McInerney probes Unicycive after 39% stock drop on FDA letter - CoinPost Terminal